14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ANRO vs PYPD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over PolyPid Ltd. (PYPD) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ANRO carries a Unified Composite Score of 34.3/100 (SELL) at $25.12 (N/M Forward P/E, 0.0% operating margin), whereas PYPD carries 31.1/100 (SELL) at $6.50 (N/M Forward P/E, 0.0% operating margin).
Defensive Composite Rating Caution: Although ANRO compares more favorably head-to-head, both ANRO (34.3/100 SELL) and PYPD (31.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 48.0); meanwhile PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 65.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs PYPD. Trailing 12-month operating profitability (ANRO 0.0% vs PYPD 0.0%) and valuation multiples (ANRO N/M vs PYPD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ANRO vs PYPD Key Questions & Quantitative Answers
As of Nov 17, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over PolyPid Ltd. (PYPD) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ANRO carries a Unified Composite Score of 34.3/100 (SELL) at $25.12 (N/M Forward P/E, 0.0% operating margin), whereas PYPD carries 31.1/100 (SELL) at $6.50 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although ANRO compares more favorably head-to-head, both ANRO (34.3/100 SELL) and PYPD (31.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 48.0); meanwhile PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 65.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ANRO leads the Growth & Scale pillar: ANRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PYPD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ANRO generates N/A in USD-normalized revenue versus N/A for PYPD. In operating R&D and SG&A reinvestment, ANRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PYPD.
ANRO and PYPD trade at balanced relative valuation multiples. ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANRO (-46.7% ROE) versus PYPD (-243.6% ROE) capital efficiency.
In options market volatility and institutional positioning, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.03β · 94% Vol realized risk). By comparison, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.88β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.